Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis
Status:
Terminated
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
Parapsoriasis is a term that refers to a precursor stage of cutaneous T-cell lymphoma
(CTCL)/mycosis fungoides(MF). Complete responses (clearing) of early presentations of CTCL/MF
have been shown to be associated with long-term survival and cure. Induction of a complete
response in parapsoriasis, therefore, would seem to be a desirable therapeutic endpoint.
Bexarotene 1% gel has been approved for treatment of cutaneous T-cell lymphoma (mycosis
fungoides). The goal of this study is to evaluate the tolerability, safety and efficacy of
bexarotene 1% gel in patients with parapsoriasis.